Anti-FOXA1 antibody [2F83]
| Name | Anti-FOXA1 antibody [2F83] |
|---|---|
| Supplier | Abcam |
| Catalog | ab40868 |
| Prices | $390.00 |
| Sizes | 100 µl |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Clone | 2F83 |
| Applications | WB IHC-P FC IP |
| Species Reactivities | Mouse, Human |
| Antigen | Recombinant full length protein (Human) |
| Description | Mouse Monoclonal |
| Gene | FOXA1 |
| Conjugate | Unconjugated |
| Supplier Page | Shop |
Product images
Ab40868 staining Mouse fetal lung tissue at 1:200 dilution by Immunohistochemistry paraffin embedded sections. FOXA1 was visualised by DAB (dark red colour) and counterstained with Nuclear Fast Red (pink colour). Magnification 20x.
![Anti-FOXA1 antibody [2F83] (ab40868) + Prostate Tumor Lysate Tissue Lysate at 10 µgSecondaryGoat Anti-Mouse IgG H&L (HRP) preadsorbed (ab97040) at 1/5000 dilutiondeveloped using the ECL techniquePerformed under reducing conditions.](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_2/20226_FOXA1-Primary-antibodies-ab40868-2.jpg)
Anti-FOXA1 antibody [2F83] (ab40868) + Prostate Tumor Lysate Tissue Lysate at 10 µgSecondaryGoat Anti-Mouse IgG H&L (HRP) preadsorbed (ab97040) at 1/5000 dilutiondeveloped using the ECL techniquePerformed under reducing conditions.
![Overlay histogram showing HepG2 cells stained with ab40868 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab40868, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HepG2 cells fixed with 4% paraformaldehyde (10 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.](http://www.bioprodhub.com/system/product_images/ab_products/2/sub_2/20227_FOXA1-Primary-antibodies-ab40868-5.jpg)
Overlay histogram showing HepG2 cells stained with ab40868 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab40868, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HepG2 cells fixed with 4% paraformaldehyde (10 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.
Product References
Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) alpha and - Interaction of glucocorticoid receptor (GR) with estrogen receptor (ER) alpha and
Karmakar S, Jin Y, Nagaich AK. J Biol Chem. 2013 Aug 16;288(33):24020-34.
FOXO3a nuclear localisation is associated with good prognosis in luminal-like - FOXO3a nuclear localisation is associated with good prognosis in luminal-like
Habashy HO, Rakha EA, Aleskandarany M, Ahmed MA, Green AR, Ellis IO, Powe DG. Breast Cancer Res Treat. 2011 Aug;129(1):11-21.
RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast - RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast
Habashy HO, Powe DG, Glaab E, Ball G, Spiteri I, Krasnogor N, Garibaldi JM, Rakha EA, Green AR, Caldas C, Ellis IO. Breast Cancer Res Treat. 2011 Jul;128(2):315-26.
Triple-negative breast cancer: distinguishing between basal and nonbasal - Triple-negative breast cancer: distinguishing between basal and nonbasal
Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO. Clin Cancer Res. 2009 Apr 1;15(7):2302-10.
Triple-negative breast cancer: distinguishing between basal and nonbasal - Triple-negative breast cancer: distinguishing between basal and nonbasal
Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO. Clin Cancer Res. 2009 Apr 1;15(7):2302-10.
Triple-negative breast cancer: distinguishing between basal and nonbasal - Triple-negative breast cancer: distinguishing between basal and nonbasal
Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO. Clin Cancer Res. 2009 Apr 1;15(7):2302-10.
Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in - Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in
Albergaria A, Paredes J, Sousa B, Milanezi F, Carneiro V, Bastos J, Costa S, Vieira D, Lopes N, Lam EW, Lunet N, Schmitt F. Breast Cancer Res. 2009;11(3):R40.
Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic - Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic
Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO. Eur J Cancer. 2008 Jul;44(11):1541-51.